Frequent aberrant DNA methylation of ABCB1 has been observed in highly drug-resistant and invasive cancers, making its hypomethylation-triggering factors desirable targets for transcription-based inhibition, including the regulation of histone acetylation to reverse MDR [33, 34]. Here, ABCB1 is linked to cancer.